Search Result

Results for "

Metastatic Colorectal Cancer

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (1) Akt (1) Apoptosis (5) Autophagy (3) CD3 (1) CDK (1) DNA/RNA Synthesis (2) EGFR (5) Endogenous Metabolite (2) Glucosylceramide Synthase (GCS) (1) Guanylate Cyclase (2) HSV (2) Interleukin Related (2) Ligands for E3 Ligase (1) Liposome (1) Molecular Glues (1) mTOR (1) Notch (1) Nucleoside Antimetabolite/Analog (2) Orthopoxvirus (2) p38 MAPK (2) Phosphodiesterase (PDE) (1) Radionuclide-Drug Conjugates (RDCs) (1) Ras (1) Reference Standards (1) STING (1) TAM Receptor (1) TGF-beta/Smad (3) TGF-β Receptor (2) Thymidylate Synthase (2) TNF Receptor (1) Transmembrane Glycoprotein (1) TREM receptor (1) VEGFR (2) Wee1 (1) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (30) Metabolic Disease (1)

By Targets:

ADC Antibody (1)

Akt (1)

Apoptosis (5)

Autophagy (3)

CD3 (1)

CDK (1)

DNA/RNA Synthesis (2)

EGFR (5)

Endogenous Metabolite (2)

Glucosylceramide Synthase (GCS) (1)

Guanylate Cyclase (2)

HSV (2)

Interleukin Related (2)

Ligands for E3 Ligase (1)

Liposome (1)

Molecular Glues (1)

mTOR (1)

Notch (1)

Nucleoside Antimetabolite/Analog (2)

Orthopoxvirus (2)

p38 MAPK (2)

Phosphodiesterase (PDE) (1)

Radionuclide-Drug Conjugates (RDCs) (1)

Ras (1)

Reference Standards (1)

STING (1)

TAM Receptor (1)

TGF-beta/Smad (3)

TGF-β Receptor (2)

Thymidylate Synthase (2)

TNF Receptor (1)

Transmembrane Glycoprotein (1)

TREM receptor (1)

VEGFR (2)

Wee1 (1)

Wnt (1)

β-catenin (1)

By Research Areas:

Cancer (30)

Metabolic Disease (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Targets Recommended: BCRP

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-A0061

Trifluridine 3 Publications Verification Trifluorothymidine; 5-Trifluorothymidine; TFT	Thymidylate Synthase HSV Nucleoside Antimetabolite/Analog Orthopoxvirus DNA/RNA Synthesis Apoptosis Autophagy	Cancer
Trifluridine (Trifluorothymidine) is an irreversible and orally active thymidylate synthase inhibitor, and thereby suppressing DNA synthesis. Trifluridine is an antiviral molecule used for research of HSV, rhabdovirus and orthopoxvirus infection. Trifluridine induces cell apoptosis and autophagy. Trifluridine is also an anticancer agent used in studies of metastatic colorectal cancer, gastrointestinal tumors .

HY-P99406

Petosemtamab MCLA 158	EGFR	Cancer
Petosemtamab (MCLA 158) is an anti- EGFR (K_d: 0.22 nM) and anti-LGR5 (K_d: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC) .

HY-155747

FDW028 1 Publications Verification	Autophagy Akt mTOR	Cancer
FDW028 a potent and highly selective FUT8 inhibitor. FUT8 exhibits potent anti-tumor activity by defucosylation and impelling lysosomal degradation of B7-H3 through the chaperone-mediated autophagy (CMA) pathway. FDW028 can be used for metastatic colorectal cancer (mCRC) research .

HY-P99011

Cibisatamab 2 Publications Verification	CD3	Cancer
Cibisatamab, a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells. Cibisatamab triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab can be used for colorectal cancer research .

HY-P991621

EOS006215 EOS-215	TREM receptor	Cancer
EOS006215 (EOS-215) is a humanized monoclonal antibody targeting TREM-2. EOS006215 competes with TREM2 ligands, prevents TREM2 multimerization, and blocks downstream signaling. EOS006215 inhibits efferocytosis, reprograms transcriptomic profiles of monocyte-derived macrophages, alters metabolism and immune response genes, and increases pro-inflammatory marker secretion. EOS006215 reduces metastasis burden, delays tumor growth, and reprograms the tumor microenvironment to overcome anti-PD-1 resistance. EOS006215 can be used for the research of triple negative breast cancer and colorectal cancer .

HY-160215

GFH018	TGF-β Receptor p38 MAPK TGF-beta/Smad Interleukin Related	Cancer
GFH018 is an orally active, selective and ATP-competitive TGF-βR1 inhibitor with an IC₅₀ of 40 nM. GFH018 reactivates the immune system by blocking the immunosuppression mediated by regulatory T cells and M2 macrophages. GFH018 inhibits tumor angiogenesis. GFH018 suppresses tumor growth in mouse tumor models. GFH018 can be used for the research of solid tumors, hepatocellular carcinoma, colorectal cancer, breast cancer, and relapsed/metastatic nasopharyngeal carcinoma .

HY-P99852

Dilpacimab ABT165; PR1283233	VEGFR Notch	Cancer
Dilpacimab (ABT165) is a bispecific variable domain immunoglobulin. Dilpacimab binds to and inhibits DLL4 and VEGF and acts as a tumor growth inhibitor. Dilpacimab can be used in research related to metastatic colorectal cancer and advanced solid tumors .

HY-P99406A

Petosemtamab (FUT8-KO)	EGFR	Cancer
Petosemtamab (FUT8-KO) is an anti-EGFR and anti-LGR5 monoclonal antibody expressed in CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucosyl loss enhances the ADCC effect of the antibody. Petosemtamab (FUT8-KO) leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab (FUT8-KO) can be used for research on solid tumors such as head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC) .

HY-147218

PF-07265807 ARRY-067	TAM Receptor	Cancer
PF-07265807 (ARRY-067) is a kinase inhibitor with primary targets AXL, MERTK, and TYRO3. PF-07265807 acts as an immunomodulator that cross-activates CD8 ⁺ T cells by enhancing dendritic cell function. PF-07265807 blocks downstream signal transduction of AXL and MERTK, and inhibits the proliferation and migration of tumor cells with high expression of these two kinases. PF-07265807 is applicable to research related to advanced or metastatic solid tumors, such as colorectal cancer .

HY-W181530

NCT02	Molecular Glues CDK Apoptosis Ligands for E3 Ligase	Cancer
NCT02 is a molecular glue degrader based on the E3 ubiquitin ligase DDB1 that targets CDK12 and its binding partner CCNK. NCT02 triggers the ubiquitination and proteasomal degradation of CCNK, thereby downregulating CDK12 protein levels and inhibiting its downstream signaling pathways. NCT02 can induce tumor cell apoptosis, arrest the cell cycle, and selectively inhibit the proliferation of colorectal cancer cells carrying TP53 defects or belonging to the consensus molecular subtype CMS4. NCT02 has the potential to inhibit tumor growth in in vitro and in vivo models .

HY-170704

DSPE-PEG2000-TCO	Liposome	Metabolic Disease Cancer
DSPE-PEG2000-TCO is a click chemistry coupling partner. DSPE-PEG2000-TCO undergoes a reverse electron-demand Diels-Alder click reaction to form a covalent linkage with tetrazine-modified Cetuximab (HY-P9905). DSPE-PEG2000-TCO maintains the stability of lipid nanoparticles (LNPs) and has high mRNA encapsulation efficiency, which supports cellular uptake and mRNA transfection. DSPE-PEG2000-TCO is used to prepare EGFR-targeted and APN-targeted mRNA-loaded LNPs, mediating receptor-dependent endocytosis, mRNA delivery, and intestinal epithelial transcytosis .

HY-P99215

Parsatuzumab Anti-EGFL7; RG 7414	VEGFR	Cancer
Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition .

HY-176296

Vizenpistat SR-8541A	Phosphodiesterase (PDE) STING	Cancer
Vizenpistat is an orally active ENPP1 inhibitor. Vizenpistat increases cGAMP levels, blocks 2′3′-cGAMP hydrolysis, inhibits adenosine production, regulates innate immune signaling mediated by the STING pathway, and modulates anti-tumor immune responses. Vizenpistat is applicable to research related to breast cancer and metastatic microsatellite-stable colorectal cancer .

HY-P3099

Uroguanylin (human)	Guanylate Cyclase	Cancer
Uroguanylin (human) is a natural ligand for the Guanylyl Cyclase (GCC) receptor expressed in metastatic colorectal cancer tumors. Uroguanylin (human) has anti-tumor actions in an animal model for human colon cancer .

HY-P991190

Rilogrotug AV-380	TGF-beta/Smad	Cancer
Rilogrotug (AV-380) is a humanized IgG1 monoclonal antibody targeting GDF15 .

HY-P3099A

Uroguanylin (human) TFA	Guanylate Cyclase	Cancer
Uroguanylin (human) (TFA) is a natural ligand for the Guanylyl Cyclase (GCC) receptor expressed in metastatic colorectal cancer tumors. Uroguanylin (human) (TFA) has anti-tumor actions in an animal model for human colon cancer .

HY-109051

Arfolitixorin	Endogenous Metabolite	Cancer
Arfolitixorin is a potent 5-Fluorouracil (5-FU) moderator. Arfolitixorin is an immediately active form of Folate, [6R]-5,10-methylenetetrahydrofolate ([6R]-MTHF). Arfolitixorin is potent for the research of metastatic colorectal cancer .

HY-P991188

MGD007	Transmembrane Glycoprotein	Cancer
MGD007 is a humanized IgG1 monoclonal antibody targeting GPA33. MGD007 can be used for study of Metastatic Colorectal Cancer .

HY-P991635

PF-07329640	TNF Receptor	Cancer
PF-07329640 is a humanized monoclonal antibody inhibitor targeting TNFRSF3. PF-07329640 can be used for advanced/metastatic solid tumors like non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) research .

HY-113680

KY1022	Apoptosis Ras β-catenin Wnt	Cancer
KY1022 is a small molecule destabilizing Ras via targeting the Wnt/β-catenin pathway. KY1022 can inhibit cellular EMT, metastasis and apoptosis. KY1022 can be used for the research of metastatic colorectal cancer .

HY-P991508

Sym004	EGFR	Cancer
Sym004 is a 1:1 mixture of two recombinant, human-mouse chimeric mAbs directed against nonoverlapping EGFR epitopes (mAb992 and mAb1024). Sym004 is ability to mediate rapid EGFR internalization and subsequent degradation of internalized receptors via EGFR cross-linking. Sym004 can be used for the study of metastatic colorectal cancer, head and neck (H&N) and lung cancer .

HY-160215A

GFH018 methylbenzenesulfonate	TGF-β Receptor p38 MAPK TGF-beta/Smad Interleukin Related	Cancer
GFH018 is an orally active, selective and ATP-competitive TGF-βR1 inhibitor with an IC₅₀ of 40 nM. GFH018 reactivates the immune system by blocking the immunosuppression mediated by regulatory T cells and M2 macrophages. GFH018 inhibits tumor angiogenesis. GFH018 suppresses tumor growth in mouse tumor models. GFH018 can be used for the research of solid tumors, hepatocellular carcinoma, colorectal cancer, breast cancer, and relapsed/metastatic nasopharyngeal carcinoma .

HY-A0061R

Trifluridine (Standard) Trifluorothymidine (Standard); 5-Trifluorothymidine (Standard); TFT (Standard)	Reference Standards Thymidylate Synthase HSV Nucleoside Antimetabolite/Analog Orthopoxvirus DNA/RNA Synthesis Apoptosis Autophagy	Cancer
Trifluridine (Standard) is the analytical standard of Trifluridine. This product is intended for research and analytical applications. Trifluridine (Trifluorothymidine) is an irreversible and orally active thymidylate synthase inhibitor, and thereby suppressing DNA synthesis. Trifluridine is an antiviral molecule used for research of HSV, rhabdovirus and orthopoxvirus infection. Trifluridine induces cell apoptosis and autophagy. Trifluridine is also an anticancer agent used in studies of metastatic colorectal cancer, gastrointestinal tumors .

HY-109051C

Arfolitixorin sulfate	Endogenous Metabolite	Cancer
Arfolitixorin sulfate is a potent 5-Fluorouracil (5-FU) moderator. Arfolitixorin sulfate is an immediately active form of Folate, [6R]-5,10-methylenetetrahydrofolate ([6R]-MTHF). Arfolitixorin sulfate is potent for the research of metastatic colorectal cancer .

HY-P991507

SCT200 Demupitamab	EGFR	Cancer
SCT200 is a fully humanized IgG1 anti-EGFR monoclonal antibody with a K_d of 0.08 nM. SCT200 can kill tumor cells by complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) through the Fc. SCT200 can be used for the study of refractory RAS and BRAF wild-type metastatic colorectal cancer .

HY-183278

APO-50815	Wee1 Apoptosis	Cancer
APO-50815 is a WEE1 kinase inhibitor with a human IC₅₀ of 9 nM. APO-50815 induces DNA damage, replication stress, S-phase cell accumulation, and apoptosis. APO-50815 can be used for the research of metastatic colorectal cancer .

HY-P992339

cT84.66	Radionuclide-Drug Conjugates (RDCs)	Cancer
cT84.66 is a highly efficient tumor-targeting agent against carcinoembryonic antigen (CEA). cT84.66 engages in bivalent binding with CEA via variable region antigen-binding sites, enabling precise targeting of CEA-producing tumor cells for delivery of therapeutic radiation. cT84.66 exhibits high tumor uptake rate, rapid clearance rate, and excellent tumor-to-blood ratio. With dual functions as an imaging agent and an antibody-directed radiotherapy agent, cT84.66 is widely used in studies of colorectal cancer and metastatic CEA-positive malignancies .

HY-P992130

Rolditamig TQB2102 Antibody	ADC Antibody EGFR	Cancer
Rolditamig (TQB2102 Antibody) is a recombinant humanized anti-human epidermal growth factor receptor 2 (HER2) antibody. Rolditamig can be conjugated with an enzyme-cleavable linker and a topoisomerase I inhibitor to form the ADC TQB2102. Rolditamig is applicable to research on solid tumors such as HER2-positive breast cancer .

HY-181989

CAIF	Glucosylceramide Synthase (GCS)	Cancer
CAIF is an irreversible, selective allosteric covalent inhibitor of ucosyltransferase 8 (FUT8) with an IC₅₀ of 5.7 μM. CAIF inhibits core fucosylation modification in cancer cells, and suppresses the invasion and migration of cancer cells. CAIF is applicable for cancer research .

Cat. No.	Product Name	Target	Research Area